secwatch / observer
8-K filed April 28, 2026, 7:59 PM ET ticker QUCY CIK 0001874252
other material confidence high sentiment negative materiality 0.90

Quantum Cyber N.V. (QUCY): M&A transaction — Quantum Cyber N.V. issues $6M preferred shares; David Lazar gains >95% voting control and Co-CEO resigns

Quantum Cyber N.V.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Avraham Ben-Tzvi

Director
QUCY · Quantum Cyber N.V.
Effective
2026-04-22
Filed
April 28, 2026, 7:59 PM ET
On April 22, 2026, our shareholders approved at an Extraordinary General Meeting the appointment of David Natan and Avraham Ben-Tzvi to our board of directors, and Mr. Natan and Mr. Ben-Tzvi became directors of our company.
Appointed

David Natan

Director
QUCY · Quantum Cyber N.V.
Effective
2026-04-22
Filed
April 28, 2026, 7:59 PM ET
On April 22, 2026, our shareholders approved at an Extraordinary General Meeting the appointment of David Natan and Avraham Ben-Tzvi to our board of directors, and Mr. Natan and Mr. Ben-Tzvi became directors of our company.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Quantum Cyber N.V. issued 1,000,000 of our series D preferred shares of preferred stock to David E. Lazar for additional $3 million.

Security
preferred stock
Shares
1,000,000 of our series D preferred shares
Purchaser
David E. Lazar
Consideration
additional $3 million
Exact text from the filing
The Second Closing Shares were issued (we received a pre-payment of $3 million for the Second Closing Shares in March of 2026).
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Quantum Cyber N.V. issued 1,000,000 of our series E preferred shares of preferred stock to David E. Lazar for additional $3 million.

Security
preferred stock
Shares
1,000,000 of our series E preferred shares
Purchaser
David E. Lazar
Consideration
additional $3 million
Exact text from the filing
The Second Closing Shares were issued (we received a pre-payment of $3 million for the Second Closing Shares in March of 2026).
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Avraham Ben-Tzvi was appointed as Director at Quantum Cyber N.V..

Action
appointed
Role
Director
Exact text from the filing
On April 22, 2026, our shareholders approved at an Extraordinary General Meeting the appointment of David Natan and Avraham Ben-Tzvi to our board of directors, and Mr. Natan and Mr. Ben-Tzvi became directors of our company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

David Natan was appointed as Director at Quantum Cyber N.V..

Action
appointed
Role
Director
Exact text from the filing
On April 22, 2026, our shareholders approved at an Extraordinary General Meeting the appointment of David Natan and Avraham Ben-Tzvi to our board of directors, and Mr. Natan and Mr. Ben-Tzvi became directors of our company.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Quantum Cyber N.V.: Amended Articles of Association to authorize preferred share conversions, change company name from Mainz Biomed N.V. to Quantum Cyber N.V., and increase authorized share capital (effective 2026-04-22).

Change
charter amendment
Effective
2026-04-22
Exact text from the filing
On April 22, 2026, we amended our Articles of Association. The material changes resulting from such amendment were: (a) the authorization of the conversion of each Series A Preferred Share into nine (9) Ordinary Shares; (b) the authorization of conversion of each Series B Preferred Share into nine (9) Ordinary Shares; (c) the authorization of the conversion of each Series C Preferred Share into nine (9) Ordinary Shares; (d) the authorization of the conversion of each Series D Preferred Share into two-hundred and twenty-five (225) Ordinary Shares; and (e) the authorization of the conversion of each Series E Preferred Share into two-hundred and twenty-five (225) Ordinary Shares; (f) the change of our name from "Mainz Biomed N.V." to "Quantum Cyber N.V."; and (g) an increase in (i) the number of authorized Ordinary Shares that we may issue from 45,000,000 to up to 900,000,000 and (ii) the number of authorized Preferred Shares that we may issue from 5,000,000, split into 1,000,000 Series A
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Quantum Cyber N.V. underwent a change of control involving David E. Lazar (closed 2026-04-22).

Action
change of control
Counterparty
David E. Lazar
Closing
2026-04-22
Exact text from the filing
On February 13, 2026, we entered into the Purchase Agreement with David Lazar, the First Closing Shares were issued on February 17, 2026, and the Second Closing Shares were issued on April 22, 2026. As a result of the transactions set out in the Purchase Agreement, Mr. Lazar became the holder of over 95% of the voting rights of our issued and outstanding shares, on a fully-diluted basis, and became the controlling shareholder.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Quantum Cyber N.V. entered into Securities Purchase Agreement with David E. Lazar valued at $3 million (effective 2026-02-13).

Action
entry
Agreement
equity purchase
Counterparty
David E. Lazar
Value
$3 million
Effective
2026-02-13
Exact text from the filing
we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with David E. Lazar on February 13, 2026 that provided for the sale in a private placement of:
View on SEC.gov

32 equity issuances filed in the last 30 days. Browse all equity issuances →

Quantum Cyber N.V. filing history →

Source: SEC EDGAR
accession 0001213900-26-048635
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.